Revance Therapeutics (RVNC) Misses Q2 EPS by 2c

Revance Therapeutics (NASDAQ: RVNC) reported Q2 EPS of ($0.88), $0.02 worse than the analyst estimate of ($0.86). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $70 thousand.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Wells Fargo cuts Netflix rating on engagement risk, weak slate
• Lumentum shares rise on analyst upgrades, AI demand outlook